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The main objective of the study was to compare the long-term safety and tolerability of fenoterol hydrobromide
delivered using a metered-dose inhaler formulated with the alternative propellant, hydrofluoroalkane 134a (HFA-
MDI), with delivery using the currently available chlorofluorocarbon MDI (CFC-MDI; Berotec1 100). A further
objective was to compare the ecacy of fenoterol HFA-MDI with fenoterol CFC-MDI, using the pulmonary
function parameters of forced expiratory volume in 1 sec (FEV1), forced vital capacity (FVC) and peak expiratory
flow (PEF). Following a 2-week run-in phase, a 12-week, double-blind parallel group comparison was undertaken
in 290 patients randomized on a 2:1 basis to two puffs of 100 mg fenoterol four times a day (HFA-MDI¼197
patients; CFC-MDI¼93 patients). A total of 236 patients in this multi-centre study completed the trial as planned.
The overall incidence of adverse events (AEs) was similar in both groups (29?9% of HFA-MDI patients and 28% of
CFC-MDI patients). Reports of respiratory disorder AEs were also comparable (21?8% HFA-MDI; 22?6% CFC-
MDI). End of study laboratory tests, ECG, pulse, blood pressure and physical examination showed no significant
differences from pre-study baselines in either group and both treatments appeared to be well tolerated. Pre-dose
FEV1 measurements taken at the three clinic visits were constant and increase in FEV1 at 5 and 30min post-dose
demonstrated equivalent ecacy for the two formulations. No difference between the two groups was observed in
PEF or in the use of rescue medication. We conclude from these findings that the long-term safety and ecacy
profile of fenoterol HFA-MDI is comparable to that of the fenoterol CFC-MDI.
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Due to the ozone-depleting effect of chlorofluorocarbons
(CFCs) on the lower stratosphere, CFC-driven pressurized
metered-dose inhalers (CFC-MDIs) are expected to be
phased out over the next few years. The 1987 Montreal
Protocol, an international agreement to ban ozone-deplet-
ing substances, provided an exemption for the medical use
of CFCs in MDIs, but it is envisaged that all CFC-MDIs
will be replaced by 2005, or earlier where possible.
Alternative propellants and devices are therefore required
for the aerosol delivery of a range of drugs; several of theseReceived 23 March and accepted 3 April 2000.
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0954-6111/00/100948+06 $35?00/0are under development or are now available, with non-CFC
inhalers, multi-dose dry powder inhalers (DPIs) and new
propellant-free delivery systems (soft-mist inhaler) all
having potential as acceptable environmentally friendly
replacements for the CFC-MDI (1–3).
The hydrofluoroalkanes (HFA), such as 134a (1,1,1,2-
tetrafluoro-ethane), appear to be suitable alternatives to
CFCs as they do not contain chlorine and may have one or
more hydrogens (4). HFAs break down more quickly in the
atmosphere and consequently the destruction of the ozone
is reduced. Pre-clinical toxicity trials suggesting that HFA-
134a is well-tolerated and effects at exposure levels far in
excess of proposed clinical levels are similar to those
produced by the structurally related CFCs.
The present study was designed to carry out a clinical
comparison of fenoterol hydrobromide (5) inhaled as two
100mg puffs four times a day using the marketed CFC-MDI
(Berotec1 100; Boehringer Ingelheim, Germany) with the
same regimen of fenoterol administered using an MDI# 2000 HARCOURT PUBLISHERS LTD
TABLE 1. Demographics and baseline characteristics for
intention to treat patients (n¼290)*
Parameter HFA-MDI CFC-MDI
Male/female (n) 107/90 49/44
Age (years) 47?1 (13?4) 47?0 (13?0)
Median (range) duration
of asthma (years)
6 (0–53) 7 (0–55)
Smoking history (n)
never smoked 122 (62%) 61 (66%)
ex-smokers 74 (37?5%) 31 (33%)
current smokers 1 (0?5%) 1 (1%)
Systolic bp (mmHg) 130 (15) 133 (17)
Diastolic bp (mmHg) 82 (8) 83 (9)
Pulse (bpm) 78 (10) 80 (11)
Pre-dose FEV1 1?98 (0?66) 2?01 (0?61)
Pre-dose FVC 2?94 (0?92) 2?93 (0?87)
FEV1/FVC(%) 68 (12) 69 (13)
FEV1 (% pred.) 61 (13) 62 (11)
FEV1 reversibility (%) 32 (21) 30 (13)
*Figures are means (SD) unless otherwise stated.
SAFETY AND EFFICACY OF HFA-MDI OR CFC-MDI IN ASTHMA 949driven by the alternative propellant HFA-134a. The main
aim of the trial was to assess the long-term safety of
fenoterol HFA-MDI in comparison with the standard
fenoterol CFC-MDI in patients with asthma. The incidence
of adverse events, use of rescue medication, laboratory
assessments, ECG, vital signs and physical examination
were the primary safety endpoints used in the trial. An
additional trial objective was to monitor evidence of any
switch effect in those patients who changed from fenoterol
CFC-MDI in the run-in phase to fenoterol HFA-MDI for
the 12-week controlled treatment phase.
Ecacy of fenoterol HFA-MDI was evaluated against
CFC-MDI using the following pulmonary function para-
meters: forced expiratory volume in 1 sec (FEV1) and forced
vital capacity (FVC), both measured pre-dose and at 5 and
30min post-dose at clinic visits, as well as daily morning
and evening pre-dose peak expiratory flow (PEF).
Methods
STUDY POPULATION
Male or female outpatients aged 18–65 years who were
current non-smokers with a smoking history of 10 pack
years were eligible for inclusion in the study if they had a
diagnosis of stable bronchial asthma, as partly defined by
the American Thoracic Society (6), and needed to use
inhaled bronchodilators on a regular basis. Patients were
required to have an FEV1 of 40–80% of the predicted
normal value when off bronchodilator medication, based
on The European Community for Coal and Steel guidelines
for lung function testing (7), and be able to demonstrate a
15% improvement in FEV1 within 30min of inhaling two
puffs of 100 mg fenoterol via Berotec1 100 CFC-MDI. At
the pre-study screening, patients also had to demonstrate
that they could use a peak flow meter, perform pulmonary
function tests, were able to self-administer bronchodilator
drugs via an MDI without a spacer and complete a study
diary correctly.
Those who had a history of clinically significant
cardiovascular, renal, neurological, liver or endocrine
disease within the last 3 years were excluded, as were
subjects with a history of cystic fibrosis, bronchiectasis, or
life-threatening pulmonary obstruction. An upper respira-
tory tract infection or hospitalization due to an exacerba-
tion of asthma 4 weeks prior to the start of the run-in phase
also prevented enrolment. Oral and inhaled short-acting b2-
agonists were not permitted for 18 h and 8 h, respectively,
before the initial screening phase, while long-acting oral
and inhaled b2-agonists were not permitted 36 h and 48 h
prior to the screening phase. Subjects taking 410mg
prednisolone or equivalent during the 4 weeks immediately
prior to the screening phase were excluded. Anticholiner-
gics were excluded for at least 7 days (oral) or 8 h (inhaled)
before the start of the screening visit. None of the above
medications was permitted during the study. A wash-out
period of at least 48 h prior to pulmonary function testing
was required for theophylline and antihistamines (exceptastemizole for which a time lapse of at least 96 h was
required).
The study was carried out between May 1994 and
September 1995 in 46 study centres in Germany. A total of
363 patients were screened, from which 361 were eligible for
entry to the run-in phase. Of these, 291 were suitable for
randomization to treatment. As one patient received
incorrect trial medication for the first 6 weeks of the study,
the intention to treat analyses are based on 290 patients.
The demographics and baseline characteristics of the study
population are shown in Table 1. Total withdrawals
numbered 55 (19%), comprising 42 (21%) patients from
the HFA group and 13 (14%) from the CFC group. The
reasons for withdrawal are detailed in Table 2.
The trial was reviewed and approved by the Ethics
Committee of the Rhineland-Palatinate Federal Chamber
of Physicians and carried out in accordance with the
principles of the Declaration of Helsinki. Written, informed
consent to participate in the trial was obtained from all
patients before commencement.
STUDY DESIGN
The study used a multi-centre, randomized, double-blind,
parallel group design. The study design is outlined in Fig. 1.
The 361 subjects who met the enrolment criteria began a 2-
week run-in phase during which each patient received
200mg (two puffs) of fenoterol CFC-MDI four times a day
and, if needed, rescue medication (salbutamol
100mg puff71) via CFC-MDI. On completion of the run-
in period, 291 eligible patients were randomly assigned to
continue with fenoterol CFC-MDI (one third of patients)
or to be switched to fenoterol HFA-MDI (two thirds of
patients) at the same regimen for 12 weeks, which
TABLE 2. Reasons for patient withdrawal
HFA-MDI CFC-MDI Total
Randomized 198 (100%) 93 (100%) 291 (100%)
Discontinued 42 (21%) 13 (14%) 55 (19%)
worsening of disease under study 5 (3%) 2 (2%) 7 (2%)
worsening of other pre-existing disease 0 (0%) 0 (0%) 0 (0%)
other adverse event 6 (3%) 2 (2%) 8 (3%)
lack of ecacy 1 (1%) 1 (1%) 2 (1%)
non-compliant with protocol 12 (6%) 3 (3%) 15 (5%)
lost to follow-up 10 (5%) 4 (4%) 14 (5%)
consent withdrawn 5 (3%) 0 (0%) 5 (2%)
other 3 (2%) 1 (1%) 4 (1%)
Completed 156 (79%) 80 (86%) 236 (81%)
950 J. GOLDBERG ET AL.corresponded to the maximum recommended dosage for
regular treatment. Three clinic visits were made during the
12-week test phase at days 1, 43 and 85 with patients
receiving a 6-week supply of the assigned study medication
at day 1 and day 43. Matched and coded drug supplies were
used for patient and investigator blinding, with neither
group aware of the randomization scheme. As fenoterol
CFC-MDIs and HFA-MDIs differ in appearance, a plastic
cover was devised to preserve blinding during the 12-week
treatment phase of the study.
STUDY MEASUREMENTS
The study investigators recorded any observed adverse
events during the study and adverse events reported by
patients at each clinic visit on day 1, 43 and 85 of the 12-
week study phase, including date and time of onset and end
of event, outcome, intensity, causal relationship to study
drug and any treatment initiated. Particular attention was
given to cough, wheezing and paradoxical bronchospasm
(defined as a 15% fall below baseline FEV1), and to theFIG. 1. Study design. One patient excluded from data analysesneed for rescue medication (salbutamol 100mg puff71)
within 30min of inhalation. Blood pressure and pulse were
monitored in the seated position pre-dose and 5, 15 and
30min post dose on test days 1, 43 and 85 prior to lung
function testing. A 12-lead ECG was carried out at each
clinic visit before and 45min following test drug inhalation.
Using a spirometer, three FEV1 and FVC measurements
were taken 10min before, and 5 and 30min following
inhalation via HFA-MDI or CFC-MDI during clinic visits
and the highest values recorded. Patients used a Healthscan
Personal Best1 (Healthscan Products Inc., Cedar Grove,
NJ, U.S.A.) peak flow meter to record the best of three
morning and evening PEF rates in a daily diary. Physical
examinations, laboratory screens and 12-lead ECGs were
carried out on recruitment and at the end of the study.
STATISTICAL ANALYSIS
The experimental treatments were allocated in an unba-
lanced fashion: two thirds of all patients to fenoterol
HFA-MDI vs. one third to fenoterol CFC-MDI. A 2:1as received incorrect medication.
FIG. 2. Overall incidence of adverse events and most
common respiratory events (n¼290). &: CFC-MDI; &:
HFA-MDI.
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patients to the test formulation HFA-MDI. At the same
time, the size of the control group kept the balance between
the requirements to draw valid conclusions and to keep the
overall number of patients as small as possible. As this was
primarily a safety study, no differentiation was made
between primary and secondary endpoints. In terms of
ecacy, the trial was designed to demonstrate that
fenoterol HFA-MDI is not inferior to CFC-MDI with
regard to increase in FEV1 at 5 and 30min post dose. Non-
inferiority was determined according to the method
proposed by Westlake (8) by testing the null hypothesis:
fenoterol HFA-MDI–fenoterol CFC-MDI 0?15 l at a one-
sided error level of a¼0?05.
A sample size of 110 HFA-MDI patients and 55 CFC-
MDI patients was calculated to conclude non-inferiority at
5% level of significance, given that the formulations are
equal. These numbers were increased to 150 HFA-MDI
patients and 75 CFC-MDI patients to be able to detect a
2% incidence rate of adverse events in the fenoterol HFA-
MDI group with a power of 95%. Observed cases analysis
(based on patients with data on a given test day) excluding
patients with major protocol violations was used as primary
analysis. For patients who discontinued the study during
the 12-week randomized period, no individual patient data
were carried forward. Mean weekly PEF was calculated for
any of the weekly intervals in which data were available for
at least 4 days.
Increase in FEV1 and FVC at 5 and 30min post-dose
were analysed separately for each time-point using analysis
of covariance (ANCOVA) with the test-day pre-dose value
as a covariate and the main effects centre and treatment.
These analyses were followed by one-sided equivalence
tests. Pre-dose FEV1 and FVC on days 43 and 85 were
analysed separately for each clinic visit using ANCOVA
with day 1 pre-dose FEV1 or FVC as a covariate. The mean
weekly morning and evening PEF rates were analysed by
ANCOVA with the respective mean weekly increase in the
last week of the run-in period as a covariate and treatment
as the main effect. Mean weekly sums of rescue medication
were analysed by non-parametric Wilcoxon rank sum tests.
The incidence of adverse events were tabulated by treat-
ment.
Results
Two hundred and thirty-six patients completed the study:
156 (79%) of the HFA-MDI group and 80 (86%) of the
CFC-MDI group. Forty-two (21%) of the 197 patients
randomized to fenoterol HFA-MDI discontinued the study
compared with 13 (14%) of 93 patients randomized to
fenoterol CFC-MDI. Eleven (6%) patients in the HFA-
MDI group and four (4%) patients in the CFC-MDI group
withdrew due to adverse events. However, of the 16 patients
who dropped out of the HFA group during the early part of
the 12-week treatment phase (22 days), only four
discontinued the study as a result of respiratory adverse
events, and one as a result of known side effects of b2-
agonists (tremor and restlessness). Of the remaining 11early withdrawals, seven gave no explanation for disconti-
nuing and four were withdrawn for reasons unrelated to the
study.
Overall, the incidence of adverse events in the 290
randomized patients was comparable between the two
groups with 29?9% (59 patients) receiving fenoterol HFA-
MDI and 28% (26 patients) randomized to fenoterol CFC-
MDI reporting adverse events. Respiratory adverse events
were most common with asthma, bronchitis, cough,
dyspnoea and rhinitis heading the list (Fig. 2). A similar
incidence of respiratory disorders was observed in the
two groups with events occurring in 43/197 HFA-MDI
patients (21?8%) and 21/93 CFC-MDI patients (22?6%).
However, during the first 2 weeks of the study phase
there was a slight increase in the incidence of respiratory
adverse events reported by patients who were randomized
to HFA-MDI [14 patients (7?1%) vs. four patients
(4?3%) continuing in the CFC-MDI group]. The incidence
of respiratory events considered treatment-related was
balanced across both groups, while that of all treatment-
related adverse events was slightly higher in the HFA-MDI
group (6% vs. 2%). None of the serious adverse events
that occurred in nine patients (one fatal) was judged
treatment-related by the study investigators and these
events were equally distributed between the two fenoterol
MDI groups.
There were no clinically significant differences between
the fenoterol HFA- and CFC-MDI groups with regard to
laboratory tests carried out at baseline and on completion
of the study. Abnormally high findings of eosinophils,
basophils, monocytes, glucose and potassium were ob-
served in both treatment groups at the end of the study
(48% of patients in at least one treatment group showed
an increase towards abnormally high values). Blood
pressure and pulse readings taken 5min following inhala-
tion of fenoterol HFA-MDI or CFC-MDI on days 1, 43
and 85 of the study period showed no marked change from
pre-dose values. ECGs performed pre- and 45min post-
dose on the three test days showed no clinically relevant
differences between the HFA and CFC treatments, or
between pre- and post-dose measurements. There was no
difference in the use of rescue medication (salbutamol
100mg via CFC-MDI as needed) between the two
treatments. Paradoxical bronchospasm, defined as a
FIG. 4. Mean weekly morning and evening pre-dose PEF
adjusted for baseline values (per protocol data set;
n¼270). *–*: HFA-MDI; *–*: CFC-MDI.
952 J. GOLDBERG ET AL.decrease in FEV1 of 415% within 30min of inhaling the
study drug, was a rare occurrence, experienced by three
patients in each of the HFA and CFC groups on day 1, and
by one patient on day 43 and day 85 in the HFA group. As
a result of this low incidence no treatment effect could be
observed.
The ecacy results demonstrate that the long-term
ecacy profile of fenoterol administered using the HFA-
MDI is comparable to that of the CFC-MDI. Due to
protocol violations for the various pulmonary function
analyses, the number of evaluable patients varied according
to the respective analysis. As a result the per-protocol data
for spirometric tests is based on 275 patients while
data from 270 patients has been examined for the PEF
analyses.
Mean pre-dose FEV1 values were similar throughout the
12-week study period both within and between the HFA
and CFC groups (n¼275), at days 1, 43 and 85 (2?105/
2?111 l; 2?174/2?092 l; and 2?205/2?118 l, respectively). Ra-
pid increases in FEV1 following inhalation of two puffs of
100 mg fenoterol via the HFA-MDI or CFC-MDI were
observed on the test days within 5min of inhaling the drug.
Fig. 3 shows that this effect was more pronounced 30min
after administration in both the HFA and CFC patient
groups. The increase in FEV1 at 5 and 30min post-dose in
the HFA-MDI group was significantly equivalent to that
obtained with the CFC-MDI at all clinic visits (P50?01
throughout), using an equivalence limit of 0?15 l. Over the
12 weeks study phase, pre-dose FVC increased slightly in
the HFA group. Post-dose FVC data analysis supported
the FEV1 results with the increase in FVC in patients
randomized to the HFA-MDI equivalent to that observed
with the CFC-MDI.
Morning and evening mean pre-dose PEF also increased
slightly during both the 2-week run in period and 12-week
treatment period (mean average increase 15 lmin71), but
no significant statistical or clinical treatment difference was
observed either for morning or evening PEF (Fig. 4). The
mean morning PEF data for the first week of the treatment
phase shows that no switch-effect was apparent in patients
randomized to the HFA-MDI [HFA¼301 lmin71
CFC¼300 lmin71; P¼0?8469; 90%CI for the difference
(HFA–CFC) 77?7 lmin71; 9?8 lmin71)]; the evening PEF
data yielded similar findings.FIG. 3. Time-response curves for mean unadjusted FEV1
(per protocol data set; n¼275). *–*: HFA-MDI; *–*:
CFC-MDI.Discussion
For more than 40 years (9), the MDI has been an effective
device for the delivery of drugs used in the treatment of
respiratory diseases and has an excellent safety record.
However, given the present environmental concerns that
surround the use of CFCs and other substances, the parties
to the Montreal Protocol have agreed that MDIs driven by
chlorofluorocarbons are no longer tenable. Member coun-
tries of the European Union have agreed that no new
agents that require a CFC propellant should be developed.
Similar restrictions have been introduced in other countries.
As a result, although the essential use status granted to
CFC-containing MDIs under the Montreal Protocol is
secure for the present, it is clear that alternative propellants
such as HFA-134a will inevitably replace CFC-MDIs,
currently used by an estimated 70 million patients world-
wide (10). Some members of this large patient population
(and some physicians) will no doubt have serious concerns
about relinquishing a form of medication that they have
found to be ecacious, reliable, well-tolerated and easy to
use. It is therefore essential that both the medical and lay
communities are assured that the levels of safety and
ecacy obtainable with alternative propellants or new
delivery systems are equivalent or superior to those
obtained with CFC-MDIs.
Various pre-clinical and clinical studies using HFA
propellants to deliver bronchodilatory or anti-inflamma-
tory agents have demonstrated that HFAs are equivalent to
standard therapy (11–14). The results from our study
concurred with these previous findings and demonstrated
that the long-term safety and ecacy profile of fenoterol
800mg day71 delivered via the HFA-MDI was comparable
to the CFC-MDI in patients with asthma.
The overall incidence of adverse events was very similar
between the two treatments. Respiratory system disorders
were comparable for the most part, with events such as
asthma and bronchitis equally distributed between the
HFA and CFC patients. However, a higher incidence of
dyspnoea was observed in the HFA group, reported by
4?1% of HFA patients compared with 1?1% of CFC
patients. This could be a chance finding as dyspnoea is a
common symptom of asthma and bronchitis, conditions for
which there were no significant differences between the
SAFETY AND EFFICACY OF HFA-MDI OR CFC-MDI IN ASTHMA 953groups. While a small increase in respiratory adverse events
in HFA patients was noted during weeks 1 and 2 of the
study phase, this switch effect was not marked and may
simply be a reflection of the known sensitivity of asthma
patients to changes in treatment.
Analysis of the need for rescue medication among study
participants over the 12-week randomization period
showed that there was no difference in the use of
salbutamol 100mg between the two groups of patients.
Investigations related to blood pressure, pulse. ECG and
laboratory tests performed during clinic visits did not
indicate that there were any clinically relevant differences
between the two formulations. The percentage of patients
with abnormal findings in laboratory parameters was also
comparable. One fatality and eight serious adverse events
occurred during the study, but none of these was judged to
be treatment-related and they were distributed equally
across the HFA-MDI and CFC-MDI groups.
The lung function variables FEV1, FVC and PEF showed
that fenoterol delivered via HFA-MDI offered an ecacy
profile that matched that of the CFC-MDI. Pre-dose FEV1
changed little over the treatment phase but on days 43 and
85 the mean pre-dose FEV1 was slightly higher in the
fenoterol HFA-MDI group. However, the difference was
not statistically significant. The FEV1 response at 5 and
30min following treatment with the test drug formulation
was significantly non-inferior (P50?01) to that obtained
with the marketed formulation at all clinic visits using an
equivalence limit of 0?15 l, again confirming the broncho-
dilatory ecacy of the HFA-MDI. This was also supported
by the FVC analyses; highly significant results (P50?01)
were obtained with the one-sided equivalence tests for all
time points at all clinic visits.
In each group, morning and evening pre-dose PEF
increased both during the 2-week run-in phase and the 12-
week treatment phase. This improvement in PEF may be
due to better disease management in the trial situation. No
switch effect was apparent for week 1 of the randomized
treatment period for those using the fenoterol HFA-MDI.
Our study found that the long-term safety and ecacy
profile of the alternative propellant HFA was comparable to
the CFC-MDI for the administration of fenoterol. This
evidence should reassure patients with asthma but other
issues related to CFC-free devices, such as differences in taste
and delivery, also need to be addressed. Education of patients
and prescribers is paramount to ensure a smooth transition
from CFC-MDIs to the various new types of inhalers.
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